Rivaroxaban (BAY 59‐7939) is an oral, direct factor Xa inhibitor in advanced development.
This study was undertaken to investigate its effects on thrombin generation. In this placebo …

Rivaroxaban (BAY 59‐7939) is an oral, direct Factor Xa inhibitor in advanced clinical
development for the prevention and treatment of thromboembolic disorders. This was a …

Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the
blood coagulation pathway leading to thrombin generation and clot formation. It is selective …

Rivaroxaban, an oral, direct factor Xa inhibitor, is currently used in clinical practice for the
prevention and treatment of thromboembolic disorders. This single‐center, three‐way …

Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose …

Although results of some phase III clinical trials of new oral anticoagulants are now known, it
is important to understand the mechanisms of their actions. These new agents exert their …

What is already known about this subject• Rivaroxaban is a novel anticoagulant with
predictable, dose‐proportional pharmacokinetics and pharmacodynamics in healthy …

Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa
and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma …

Purpose. The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …

A randomized, single‐blind, placebo‐controlled, parallel‐group study was conducted to
assess the effect of age and gender on the pharmacokinetics and pharmacodynamics of …